{"id":"NCT03304379","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip","officialTitle":"Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-26","primaryCompletion":"2019-12-13","completion":"2020-11-09","firstPosted":"2017-10-09","resultsPosted":"2023-02-24","lastUpdate":"2023-02-24"},"enrollment":1650,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis, Knee","Osteoarthritis, Hip"],"interventions":[{"type":"DRUG","name":"Fasinumab","otherNames":["REGN475","MT-5547"]},{"type":"OTHER","name":"Diclofenac","otherNames":["ZORVOLEX"]},{"type":"OTHER","name":"Celecoxib","otherNames":["CELEBREX"]},{"type":"DRUG","name":"Matching placebo","otherNames":[]}],"arms":[{"label":"Dosing regimen 1","type":"EXPERIMENTAL"},{"label":"Dosing regimen 2","type":"EXPERIMENTAL"},{"label":"Dosing regimen 3","type":"EXPERIMENTAL"},{"label":"Dosing regimen 4","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.\n\nThe secondary objectives of the study are:\n\n* To evaluate the efficacy of fasinumab compared to non-steroidal anti-inflammatory drugs (NSAID)s, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip\n* To assess the safety and tolerability of fasinumab compared to placebo and compared to NSAIDs, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip","primaryOutcome":{"measure":"Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo","timeFrame":"Baseline up to Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-2.21,"sd":0.165},{"arm":"Fasinumab 1 mg","deltaMin":-2.84,"sd":0.127}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.0003"},{"comp":"OG000 vs OG001","p":"> 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":71,"countries":["United States"]},"refs":{"pmids":["40001000"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":309},"commonTop":["Headache","Arthralgia","Urinary tract infection","Back pain","Nasopharyngitis"]}}